Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and ...
Zacks Investment Research on MSN
CTMX stock rallies on strong phase I colorectal cancer study data
Shares of CytomX Therapeutics CTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors.
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...
Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript March 4, 2026 Verastem, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.49. Operator: Good ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results